Representativeness of CDC’s Active Bacterial Core surveillance network for infant invasive Group B Streptococcus disease in anticipation of post-licensure evaluation of maternal vaccines in the United States, 2025
- Presentation Day/Time: Thursday, April 23, 10:05 AM
- Presenter: Emmanuel Angmorteh Mensah, DrPH, MPH, MA, National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases
The Issue
- Group B Streptococcus (GBS) is a leading cause of invasive bacterial disease (e.g., sepsis) among infants. Introduction of maternal vaccines to prevent infant GBS disease is possible within five years. CDC's Active Bacterial Core surveillance (ABCs) platform will be useful for maternal GBS vaccine evaluation.
What We Did
- We assessed representativeness of the current ABCs catchment area and how a potential expansion plan to increase the sample size available for vaccine evaluation studies would affect representativeness.
What We Found
- Most sociodemographic indicators showed that the current ABCs catchment area closely aligns with the U.S. population. Three indicators (% Black; % Hispanic; % living in metropolitan counties) differed moderately, but a proposed expansion plan reduced differences.
What This Means
- ABCs is well-positioned to support post-licensure evaluation of maternal GBS vaccines. Evaluations of catchment area expansion options provide useful insight into how representativeness may shift and are essential for vaccine evaluation preparedness.
